Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
Tweet Send to a Friend
Chardan Capital Markets reiterated a Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $16.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE